Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
exenatide-human serum albumin fusion protein
- Development stage
- Phase 2
- Lead developer
- Zhejiang Huayang Pharmaceutical
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous
01
Overview
Exenatide-human serum albumin fusion protein (E2HSA) is a long-acting recombinant fusion protein consisting of the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide fused to human serum albumin (HSA). Developed by Zhejiang Huayang Pharmaceutical, this biologic is designed to overcome the short half-life of native exenatide by utilizing the long circulatory half-life of albumin, thereby reducing the frequency of administration for patients with type 2 diabetes mellitus. By activating the GLP-1 receptor, it stimulates glucose-dependent insulin secretion, inhibits glucagon release, and slows gastric emptying, leading to improved glycemic control.
- Brand names
- Zhou Kening
- Other names
- recombinant exenatide-human serum albumin fusion protein
02
Targets
Beyond the preview
Go deeper on exenatide-human serum albumin fusion protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on exenatide-human serum albumin fusion protein.